EP Patent

EP3384938A1 — Engineered nucleic acids and methods of use thereof

Assigned to Moderna Inc · Expires 2018-10-10 · 8y expired

What this patent protects

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of viruses. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent viral infection…

USPTO Abstract

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of viruses. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent viral infection, or to improve a subject's health or wellbeing.

Drugs covered by this patent

Patent Metadata

Patent number
EP3384938A1
Jurisdiction
EP
Classification
—
Expires
2018-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Moderna Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.